All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Zentiva, Lupin collaborate on commercialising Certolizumab Pegol
The partnership aims to commercialise Certolizumab Pegol, a TNF alpha inhibitor intended to treat arthritis, plaque psoriasis, and Crohn’s disease.
Sironax grants Novartis exclusive option to acquire its brain delivery platform
Sironax is a clinical-stage biotech company focused on the discovery and development of transformational therapies that address the root causes of age-related diseases
Novartis gains Swissmedic approval for malaria treatment for infants
The new medicine, developed in collaboration with Medicines for Malaria Venture (MMV), addresses a critical gap in treating malaria in infants.
JCR, Alexion collaborate on genomic medicines using JUST-AAV
The JUST-AAV platform, which optimises adeno-associated virus (AAV) vectors for targeted delivery, will be used in five of Alexion’s programmes.
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.
KalVista secures FDA approval for Ekterly to treat HAE attacks
KalVista plans to launch Ekterly in the US immediately, allowing physicians to start prescribing the drug to treat HAE attacks.
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO and OSENVELT
STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially available in the U.S.
Chugai, Gero partner to develop therapies for age-related diseases
The collaboration will leverage Gero’s AI-driven platform for target discovery and Chugai’s antibody engineering technologies to create novel antibody drug candidates.
Biocon Biologics receives EC approval for Denosumab biosimilars
The biosimilars are designed to improve bone health by preventing complications and treating conditions such as osteoporosis and bone loss.
Brii Bio, Joincare sign licensing deal for BRII-693 in Greater China
Joincare will obtain rights to research, develop, and commercialise BRII-693 in Greater China, while Brii Bio retains the rights outside the territory.